FDA inspection
Hubei Biocause Heilen Pharmaceutical Co., Ltd.: FDA inspection ending Nov 14, 2025
FDA inspection 1296860 · Voluntary Action Indicated (VAI) · Jingmen
Key facts
| Inspection ID | 1296860 |
|---|---|
| Firm | Hubei Biocause Heilen Pharmaceutical Co., Ltd. |
| FEI number | 3007268407 |
| Address | 122 Yangwan Road |
| City | Jingmen |
| Country | China |
| Fiscal year | 2026 |
| Inspection end date | Nov 14, 2025 |
| Classification | Voluntary Action Indicated (VAI) |
| Project area | Drug Quality Assurance |
| Product type | Drugs |
At a glance
- None Citations
- 1–9 Posted citations
- No Warning letter followed
- Yes Form FDA 483 issued
- No Establishment inspection report (EIR) exists
- 1–9 Inspections at this FEI
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA inspections
FDA inspections are classified as No Action Indicated (NAI), Voluntary Action Indicated (VAI) or Official Action Indicated (OAI). Inspections of individual clinical investigators are not published here.
Source: U.S. Food and Drug Administration (FDA), inspection classification data